Patients With Del(5q) MDS Who Fail to Achieve Sustained Erythroid or Cytogenetic Remission After Treatment With Lenalidomide Have an Increased Risk for Clonal Evolution and AML Progression
Annals of Hematology - Germany
doi 10.1007/s00277-009-0846-z
Full Text
Open PDFAbstract
Available in full text
Date
October 24, 2009
Authors
Publisher
Springer Science and Business Media LLC